Careers & People
“You have an opportunity to present yourself [to investors] ]
if you think you are a good company, and say now is your ]
chance to have a look at us, and the market reacted ]
favourably. We could have f_l oated at a better time, but the ]
result could not have been more pleasing.”]
Ablynx CEO Dr Edwin Moses on the company’s
successful IPO in the second half of 2007
“If the pharma industry doesn’t succeed in changing ]
the fate for these patients, we would see a tripling ]
“The UK’s lead over the rest of
of the costs and productivity losses in the next ]
]
Europe in biotech shrinks every year.
15 years… The best cost saving for society is to ]
]
We should worry that we’re not
make sure that investment in innovation is paying ]
]
stretching out the lead. The real
off so that companies do invest in changing ]
]
challenge is to ensure the seedbed
the course of these f_i ve diseases.” ]
]
of the sector continues to be nourished.” ]
Novartis’s CEO Dr Daniel Vasella on the ageing population, modern
unhealthy lifestyles and pharma’s role in combating diabetes,
Andrew Witty, CEO of GlaxoSmithKline, calling on the
Alzheimer’s disease, cancer, cardiovascular disease and obesity
UK government to ensure the ongoing pre-eminence
of the UK in the biomedical field “In the past we could consider that ]
amlodipine [Pf_i zer’s antihypertensive ]
Norvasc, now generic] was bringing ]
“I don’t know who it is, ]
something and is a very good drug, ]
but it begs the question: ]
but it was maybe the 12th calcium ]
Why would anyone want ]
antagonist drug introduced to the ]
to be BMS’s brother-in-law?” ]
market. I don’t think that in the future ]
Unnamed observer commenting on
there will be a lot of number 12s ]
speculation over the takeover of introduced to market that become ]
ImClone Systems, before Lilly emerged
very successful.” ]
as its mystery bidder
Dr Marc Cluzel, R&D chief of Sanofi-Aventis,
on the end of the me-too drug
The year in quotes
“Patients in Japan still do not have full ]
access to new drugs and they want us ]
to approve products quickly and safely. ]
“Whether drugs are patented or not, they are ]
This is an issue that should be ]
equally important for patients.” ]
confronted squarely.”]
Daiichi Sankyo president and CEO, Takashi Shoda,
PMDA chief executive Dr Tatsuya Kondo on
on the Ranbaxy acquisition
Japan’s continuing drug lag problem
“Risk-sharing can lead to tremendous ]
“We must be able to respond ]
rewards and provide a company with ]
to new science so that as new ]
the f_l exibility to focus efforts on other ]
technology comes over the ]
areas. But you must be willing to ]
horizon and becomes ready ]
accept the loss of some control that] ]
for clinical application, our ]
comes with that decision. If you’re not ]
system can come up with a ]
comfortable relinquishing some of the ]
sensible, balanced regulatory ]
decision-making in a project, you need ]
structure to deal with it.” ]
to rethink that approach.” ]
Professor Kent Woods, CEO of the
John Goddard, senior vice-president of strategic
MHRA, on future challenges facing
planning and business development at AstraZeneca,
the UK medicines regulator
on industry’s emerging partnership models
126
www.scripnews.com/supplements Scrip 100
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128